Science & Technology
STRATEGIC COLLABORATIONS & PARTNERING

The MILs™ platform has the power and flexibility to improve cell therapies across the medical landscape, creating better, more durable clinical responses in patients.

WindMIL intends to investigate the vast possibilities that may benefit from the differentiating features of MILs to create a broad pipeline of next-generation cell therapies based on our unique and proprietary process of activating and expanding memory T cells from the bone marrow.

We are proud to have forged partnerships with Bristol Myers Squibb for the clinical study of non-small cell lung cancer (NSCLC), and with the University of Pennsylvania for exploring MILs as the basis for next-generation CAR-T therapy (CAR-MILs™).

In Cell Therapy, Cell Source Matters™

WindMIL is exploring collaborations and partnerships that leverage our unique know-how and proprietary position in bone-marrow derived immunotherapies, including opportunities with non gene-modified MILs and genetically-modified MILs.

Potential partners and collaborators are invited to contact WindMIL at inquiries@windmiltherapeutics.com.

Bristol Myers Squibb

Penn Medicine

Non Gene-modified MILs

  • Naturally tumor-specific, non gene-modified MILs recognize a broad spectrum of cancer antigens, are superior tumor cell killers and highly persistent
  • MILs (alone and in combination) are being explored to treat solids tumors and hematologic malignancies
  • Our lead clinical program explores use of MILs as a novel autologous cell therapy to treat patients with NSCLC. It is an open label, single-arm, multi-center Phase 2 study of MILs in combination with nivolumab (an immune checkpoint inhibitor)
  • WindMIL is open to collaborations to further explore use of non gene-modified MILs 

Gene-modified MILs (CAR-MILs and other opportunities)

  • Data show MILs to be a superior cell source for CAR T therapy due to their natural tumor specificity and memory T-cell phenotype, which is a less ‘exhausted’ phenotype than the effector T cells found in the peripheral blood (the source of T cells for current CAR therapies)

 

Limitations of CART Therapies

 

  • Further, at lower effector-to-target ratios, CAR-MILs are more effective than traditional CARs. WindMIL has demonstrated in vitro that the memory phenotype of CAR-MILs enhances the killing ability of MILs as demonstrated in cellular assays
  • Cell therapies based on MILs with other novel genetic modifications are also possible; for example, changes to boost cell-killing activity or modifications to counter tumor cells’ efforts to evade the immune system